Cargando…
Severe alcoholic hepatitis: current perspectives
Severe acute alcoholic hepatitis (AH) is a catastrophic disease in the natural history of alcoholic liver disease with a very high 180-day mortality. It can present as acute on chronic liver failure with worse prognosis in the presence of infections and higher grades of liver disease severity. The c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691395/ https://www.ncbi.nlm.nih.gov/pubmed/31496843 http://dx.doi.org/10.2147/HMER.S197933 |
_version_ | 1783443372035276800 |
---|---|
author | Philips, Cyriac Abby Augustine, Philip Yerol, Praveen Kumar Rajesh, Sasidharan Mahadevan, Pushpa |
author_facet | Philips, Cyriac Abby Augustine, Philip Yerol, Praveen Kumar Rajesh, Sasidharan Mahadevan, Pushpa |
author_sort | Philips, Cyriac Abby |
collection | PubMed |
description | Severe acute alcoholic hepatitis (AH) is a catastrophic disease in the natural history of alcoholic liver disease with a very high 180-day mortality. It can present as acute on chronic liver failure with worse prognosis in the presence of infections and higher grades of liver disease severity. The clinical scenario involves a patient with a recent history of heavy alcohol consumption within three months of presentation with jaundice and characteristic liver enzyme elevation pattern with coagulopathy, hepatic encephalopathy, variceal bleeding and sepsis that results in extrahepatic organ failures. Several liver disease severities and therapy response indicators are in clinical use. Even though not approved, the only recommended treatment option for patients with severe AH is corticosteroids, which is without long term survival benefit. Novel efficacious treatment options awaiting high-quality multi-center studies include liver transplantation (involves strict selection criteria), growth factor therapy and fecal microbiota transplantation. In this exhaustive review, we discuss the definitions, disease severity, histopathology, and treatment options – past, present, and future, in patients with severe alcoholic hepatitis. |
format | Online Article Text |
id | pubmed-6691395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66913952019-09-06 Severe alcoholic hepatitis: current perspectives Philips, Cyriac Abby Augustine, Philip Yerol, Praveen Kumar Rajesh, Sasidharan Mahadevan, Pushpa Hepat Med Review Severe acute alcoholic hepatitis (AH) is a catastrophic disease in the natural history of alcoholic liver disease with a very high 180-day mortality. It can present as acute on chronic liver failure with worse prognosis in the presence of infections and higher grades of liver disease severity. The clinical scenario involves a patient with a recent history of heavy alcohol consumption within three months of presentation with jaundice and characteristic liver enzyme elevation pattern with coagulopathy, hepatic encephalopathy, variceal bleeding and sepsis that results in extrahepatic organ failures. Several liver disease severities and therapy response indicators are in clinical use. Even though not approved, the only recommended treatment option for patients with severe AH is corticosteroids, which is without long term survival benefit. Novel efficacious treatment options awaiting high-quality multi-center studies include liver transplantation (involves strict selection criteria), growth factor therapy and fecal microbiota transplantation. In this exhaustive review, we discuss the definitions, disease severity, histopathology, and treatment options – past, present, and future, in patients with severe alcoholic hepatitis. Dove 2019-08-08 /pmc/articles/PMC6691395/ /pubmed/31496843 http://dx.doi.org/10.2147/HMER.S197933 Text en © 2019 Philips et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Philips, Cyriac Abby Augustine, Philip Yerol, Praveen Kumar Rajesh, Sasidharan Mahadevan, Pushpa Severe alcoholic hepatitis: current perspectives |
title | Severe alcoholic hepatitis: current perspectives |
title_full | Severe alcoholic hepatitis: current perspectives |
title_fullStr | Severe alcoholic hepatitis: current perspectives |
title_full_unstemmed | Severe alcoholic hepatitis: current perspectives |
title_short | Severe alcoholic hepatitis: current perspectives |
title_sort | severe alcoholic hepatitis: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691395/ https://www.ncbi.nlm.nih.gov/pubmed/31496843 http://dx.doi.org/10.2147/HMER.S197933 |
work_keys_str_mv | AT philipscyriacabby severealcoholichepatitiscurrentperspectives AT augustinephilip severealcoholichepatitiscurrentperspectives AT yerolpraveenkumar severealcoholichepatitiscurrentperspectives AT rajeshsasidharan severealcoholichepatitiscurrentperspectives AT mahadevanpushpa severealcoholichepatitiscurrentperspectives |